Investment
Features
FeesSafety
Academy
More
Pluang+

Strategy posts $8.3B loss as Bitcoin drops 27% in 2026, holdings now below purchase cost

Market News
30 Jul 2026
Crypto Briefing
View Source
Bearish
pluang ai news

Strategy reported an $8.33 billion operating loss in Q2 2026 due to a 27% decline in Bitcoin prices, which caused an $8.32 billion unrealized loss on its digital assets. Bitcoin traded near $64,700, below Strategy’s average purchase price of about $75,476, leading to holdings valued less than their acquisition cost. Despite the loss, the company increased its Bitcoin holdings by 25% to 843,775 coins and raised $17.06 billion through capital markets programs. Strategy also improved its financial position by reducing convertible debt and maintaining a $3.75 billion dollar reserve to cover dividends and interest obligations.

More News

Telix Pharmaceuticals to release H1 2026 financial results on August 20 with investor webcast.

Telix Pharmaceuticals to release H1 2026 financial results on August 20 with investor webcast.

Telix Pharmaceuticals announced it will release its financial results for the half-year ended June 30, 2026, on August 20, 2026. An investor webcast and conference call will be held the same day to discuss the results. Telix is a global radiopharmace...

Company Fundamentals
Neutral
51 minutes ago
Inno Holdings stock to resume Nasdaq trading July 31, delayed to noon ET.

Inno Holdings stock to resume Nasdaq trading July 31, delayed to noon ET.

Inno Holdings Inc., a Texas-based electronic products trading company, announced that its common stock will resume trading on The Nasdaq Capital Market on July 31, 2026, around noon Eastern Time. This follows a trading halt imposed by Nasdaq under Co...

Market News
Neutral
58 minutes ago
FDA advisory panel finds Replimune's RP1 effective for advanced melanoma, supporting FDA review.

FDA advisory panel finds Replimune's RP1 effective for advanced melanoma, supporting FDA review.

The FDA's advisory committee voted 10 to 3 that the efficacy results from Replimune's IGNYTE study on RP1 combined with nivolumab for advanced melanoma are evaluable and clinically meaningful. This positive outcome supports the ongoing FDA review of ...

Market News
Bullish
1 hour ago
SAP Fioneer launches Cloud Accounting Subledger to simplify multi-GAAP accounting for financial firms.

SAP Fioneer launches Cloud Accounting Subledger to simplify multi-GAAP accounting for financial firms.

SAP Fioneer has introduced its Cloud Accounting Subledger, a cloud-based solution designed to help financial institutions manage complex multi-GAAP accounting requirements. The platform consolidates accounting standards like IFRS and US GAAP into a s...

Others
Bullish
1 hour ago
DBV Technologies raises $50M via At-The-Market ADS placement on Nasdaq to fund allergy treatment development.

DBV Technologies raises $50M via At-The-Market ADS placement on Nasdaq to fund allergy treatment development.

DBV Technologies announced a $50 million capital raise through the issuance of new American Depositary Shares (ADS) under its At-The-Market (ATM) program on Nasdaq. The placement involves issuing 3.66 million ADS, each representing five ordinary shar...

Company Fundamentals
Neutral
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App